Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2025

Original Article

SGLT2 inhibitors and long-term outcomes in patients with cirrhosis

Sodium-Glucose Cotransporter 2 Inhibitors Use in Patients With Liver Cirrhosis.

Diabetes/metabolism research and reviews

Citation & Authors

Diabetes Metab Res Rev. 2025;41(5):e70070.

Fu-Shun Yen; Ming-Chih Hou; James Cheng-Chung Wei; Yu-Han Huang; Ying-Hsiu Shih; Chun-Wei Pan; Sing-Ting Wang; Chii-Min Hwu; Chih-Cheng Hsu

ABSTRACT · RESEARCH SUMMARY

Research summary

This Taiwanese National Health Insurance cohort found that SGLT2 inhibitor use in patients with diabetes and compensated cirrhosis was associated with lower risks of death (aHR 0.47; 95% CI 0.42–0.52), decompensation, hepatic failure, and hepatorenal syndrome. Longer cumulative treatment duration was also associated with lower risks. Treatment-selection and healthy-user bias remain important considerations in this observational study.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗